Docetaxel (taxotere) in the treatment of prostate cancer.

@article{Beer2003DocetaxelI,
  title={Docetaxel (taxotere) in the treatment of prostate cancer.},
  author={Tomasz M Beer and Mohammed El-Geneidi and Kristine M. Eilers},
  journal={Expert review of anticancer therapy},
  year={2003},
  volume={3 3},
  pages={261-8}
}
Docetaxel (Taxotere) is a taxoid derived from the needles of the European yew tree, Taxus baccata. With an overall prostate-specific antigen response rate of 42% in four Phase II studies, docetaxel has important single-agent activity in androgen-independent prostate cancer. Phase II studies suggest that the addition of estramustine (Emcyt) to docetaxel results in higher response rates but also increased toxicity. Docetaxel with and without estramustine is being evaluated in Phase III studies… CONTINUE READING
20 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Similar Papers

Loading similar papers…